Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.

Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.

Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.

Excluding BRCA-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer, Astra’s Duo-O suggests.

The limited activity of Reblozyl in myelodysplastic syndromes patients without ringed sideroblasts could help Geron.

Regeneron’s fianlimab could be biopharma’s most potent Lag3 project, and has shown activity in a new melanoma setting